TP53 and lung carcinoma: Rifkin and colleagues first reported a systematic review on the evidence linking germline mutations with lung cancer risk, then validated through a large case–control study of patients undergoing germline whole exome sequencing (WES) the significant association between lung cancer risk and ATM, BRCA2 and TP53 pathogenetic/likely pathogenetic germline mutations [46].